The role of apoptosis proteins and complement components in the etiopathogenesis of systemic lupus erythematosus

Bernadete L Liphaus, Maria Helena Bittencourt Kiss, Bernadete L Liphaus, Maria Helena Bittencourt Kiss

Abstract

Systemic lupus erythematosus is a prototypical autoimmune disease characterized by the deregulation of T and B cells, tissue infiltration by mononuclear cells, tissue damage and the production of autoantibodies. There is a consensus that accelerated apoptosis of circulating lymphocytes and/or impaired clearance of apoptotic bodies may increase the amount of nuclear antigens presented to T lymphocytes. This process is accompanied by autoimmune responses that can lead to the development of lupus. The dysfunction of apoptosis may be a direct consequence of alterations in proteins/genes such as Fas, Bcl-2 and C1q. Increased expression of Fas antigen could intensify the exposure of hidden antigens. The overexpression of Bcl-2 protein might inhibit the removal of auto-reactive cells, and the lack of C1q could impair the clearance of self-antigens. The complete knowledge of the role of apoptosis components in the etiopathogenesis of lupus could lead to the development of new therapies targeting the apoptotic threshold, which could result in a more specific and effective disease response compared to global immunosuppression. This review summarizes the role of each component of the apoptotic process in the pathogenesis of lupus.

Keywords: Apoptosis; Bcl-2 protein; C1q complement component; Fas protein; Systemic Lupus Erythematosus.

References

    1. Andrade F, Casciola-Rosen L, Rosen A. Apoptosis in Systemic Lupus Erythematosus. Clinical Implications. Rheum Dis Clin of North Am. 2000;26:215–27.
    1. Munoz LE, van Bavel C, Franz S, Berden J, Herrmann M, van der Vlag J. Apoptosis in the pathogenesis of systemic lupus erythematosus. Lupus. 2008;17:371–5.
    1. Rahman A, Iseberg DA. Mechanisms of Disease. Systemic Lupus Erythematosus. N Engl J Med. 2008;358:929–39.
    1. Kamradt T, Mitchinson NA. Advances in immunology: Tolerance and Autoimmunity. N Engl J Med. 2001;344:655–64.
    1. Green DR. Overview: apoptotic signaling pathways in the immune system. Immunological Reviews. 2003;193:5–9.
    1. Bijl M, Reefman E, Horst G, Limburg PC, Kallenberg CGM. Reduced uptake of apoptotic cells by macrophages in systemic lupus erythematosus: correlates with decreased serum levels of complement. Ann Rheum Dis. 2006;65:57–63.
    1. Ren Y, Tang J, Mok MY, Chan AWK, Wu A, Lau CS. Increased Apoptotic Neutriphils and Macrophages and Impaired Macrophage Phagocytic Clearance of Apoptotic Neutriphils in Systemic Lupus Erythematosus. Arthritis Rheum. 2003;48:2888–97.
    1. Shoshan Y, Shapira I, Toubi E, Frolkis I, Yaron M, Mevorach D. Accelerated Fas-Mediated Apoptosis of Monocytes and Maturing Macrophages from Patients with Systemic Lupus Erythematosus: Relevance to In Vitro Impairment of Interaction with iC3b-Opsonized Apoptotic Cells. J Immunol. 2001;167:5963–9.
    1. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, et al. The Apoptotic Ligands TRAIL, TWEAK, and Fas ligand Mediate Monocyte Death Induced by Autologous Lupus T Cells. J Immunol. 2002;169:6020–9.
    1. Ferguson TA, Stuart PM, Hendon JM, Griffith TS. Apoptosis, tolerance and regulatory T cells – old wine, new wineskins. Immunological Reviews. 2003;193:111–23.
    1. Cohen PL, Caricchio R. Genetic models for the clearance of apoptotic cells. Rheum Dis Clin of North Am. 2004;30:473–86.
    1. Huck S, Deveaud E, Namane A, Zouali M. Abnormal DNA methylation and deoxycytosine-deoxyguanine content in nucleosomes from lymphocytes undergoing apoptosis. FASEB J. 1999;13:1415–22.
    1. Flierman R, Daha MR. The clearance of apoptotic cells by complement. Immunobiology. 2007;212:363–70.
    1. Giovannetti A, Pierdominici M, Di Iorio A, Cianci R, Murdaca G, Puppo F, et al. Apoptosis in the Homeostasis of the Immune System and in Human Immune Mediated Diseases. Curr Pharmac Design. 2008;14:253–68.
    1. Zhang N, Hartig H, Dzhagalov I, Draper D, He YW. The role of apoptosis in the development and function of T lymphocytes. Cell Res. 2005;15:749–69.
    1. Liphaus BL, Goldberg AC, Kiss MHB, Silva CAA. Analyses of human leukocyte antigens class II-DR in Brazilian children and adolescents with systemic lupus erythematosus. Rev Hosp Clin Fac Med São Paulo. 2002;57:277–82.
    1. Liphaus BL, Kiss MHB, Goldberg AC. HLA-DRB1 alleles in juvenile-onset systemic lupus erythematosus: renal histologic class correlations. Braz J Med Biol Res. 2007;40:591–7.
    1. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med. 1994;179:1317–30.
    1. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. J Immunol. 1994;152:3685–92.
    1. Courtney PA, Crockard AD, Williamson K, Mcconnell J, Kennedy RJ, Bell AL. Lymphocyte apoptosis in systemic lupus erythematosus: relationships with Fas expression, serum soluble Fas and disease activity. Lupus. 1999;8:508–13.
    1. Chan EY, Ko SC, Lau CS. Increased rate of apoptosis and decreased expression of bcl-2 protein in peripheral blood lymphocytes from patients with active systemic lupus erythematosus. Asian Pac J Allergy Immunol. 1997;15:3–7.
    1. Dieker JW, van der Vlag J, Berden JH. Deranged removal of apoptotic cells: its role in the genesis of lupus. Nephrol Dial Transplant. 2004;19:282–5.
    1. Herrmann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocytosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:1241–50.
    1. Potter PK, Cortes-Hernandez J, Quartier P, Botto M, Walport MJ. Lupus-prone mice have an abnormal response to thioglycolate and an impaired clearance of apoptotic cells. J Immunol. 2003;170:3223–32.
    1. Baumann I, Kolowos W, Voll RE, et al. Imparied uptake of apoptotic cells into tingible body macrophages in germinal centers of patients with systemic lupus erythematosus. Arthritis Rheum. 2002;46:191–201.
    1. Pyrovolaki K, Mavroudi I, Sidiropolous P, Eliopoulos AG, Boumpas DT, Papadaki A. Increased Expression of CD40 on Bone Marrow CD34+ Hematopoietic Progenitor Cells in Patients with Systemic Lupus Erythematosus. Contribution to Fas-Mediated Apoptosis. Arthritis Rheum. 2009;60:543–52.
    1. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB. Fas gene mutations in the Canele-Smith Syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med. 1996;335:1643–9.
    1. Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand: a novel member of the tumor necrosis factor family. Cell. 1993;75:1169–78.
    1. Ohsako S, Hara M, Harigai M, Fukasawa C, Kashiwagaki S. Expression and function of Fas antigen and Bcl-2 in human Systemic Lupus Erythematosus lymphocytes. Clin Immunol Immunophatol. 1994;73:109–14.
    1. Amasaki Y, Kobayashi S, Takeda T, Ogura N, Jodo S, Nakabayashi T, Tsutsumi A, Fujisaku A, Koike T. Up-regulated expression of Fas antigen (CD95) by peripheral naive and memory T cell subsets in patients with systemic lupus erythematosus (SLE): a possible mechanism for lymphopenia. Clin Exp Immunol. 1995;22:245–50.
    1. Bijl M, Horst G, Limburg PC, Kallenberg CG. Fas expression on peripheral blood lymphocytes in systemic lupus erythematosus (SLE): relation to lymphocyte activation and disease activity. Lupus. 2001;10:866–72.
    1. Suzuki N, Sakame T. Abnormal Fas and Fas ligand expression of lymphocytes in patients with SLE. Nippon Rinsho. 1996;54:1955–9.
    1. Jodo S, Kobayashi S, Kayagaki N, Ogura N, Feng Y, Amasaki Y, et al. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 1997;107:89–95.
    1. Telegina E, Reshetnyak T, Moshnikova A, Proussakova O, Zhukova A, Kuznetsova A, et al. A possible role of Fas-ligand-mediated “reserse signalling” in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Immunol Letters. 2009;122:12–17.
    1. Habib HM, Taher TE, Isenberg DA, Mageed RA. Enhanced propensity of T lymphocytes in patients with systemic lupus erythematosus to apoptosis in the presence of tumour necrosis factor alpha. Scand J Rheumatol. 2009;38:112–20.
    1. Iwai Iwai K, Miyawaki T, Takizawa T, Konno A, Otha K, Yachie A, et al. Differential Expression of Bcl-2 and Susceptibility to Anti-Fas-Mediated Cell Death in Peripheral Blood Lymphocytes, Monocytes, and Neutrophils. Blood. 1994;84:1201–8.
    1. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S, et al. Enforced Bcl-2 expression in B lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci. USA. 1991;88:8661–5.
    1. Aringer M, Wintersberger W, Steiner CW, Kiener H, Presterl E, Jaeger U, et al. High levels of Bcl-2 protein in circulating T lymphocytes, but not B lymphocytes of patients with systemic lupus erythematosus. Arthritis Rheum. 1994;10:1423–30.
    1. Mehrian R, Quismorio FP, Jr, Strassmann G, Stimmler MM, Horwitz DA, Kitridou RC, et al. Synergistic effect between IL-10 and Bcl-2 genotypes in determining susceptibility to systemic lupus erythematosus. Arthritis Rheum. 1998;41:596–602.
    1. Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res. 2001;21:3053–9.
    1. Falcini F, Azzari C, Gelli VAMG, Luchetti M, Gabrielli A, Calzolari A, et al. Reduction of bcl-2 in T cells during immunossupressive therapy in patients with severe juvenile onset Systemic Lupus Erythematosus. Clin Immunol. 1999;93:59–64.
    1. Liphaus BL, Kiss MHB, Carrasco S, Goldenstein-Schainberg C. Increased Fas and Bcl-2 expression on peripheral blood T and B lymphocytes from juvenile-onset systemic lupus erythematosus, but not from juvenile rheumatoid arthritis and juvenile dermatomyositis. Clin Dev Immunol. 2006;13:283–7.
    1. Liphaus BL, Kiss MHB, Carrasco S, Goldenstein-Schainberg C. Increased Fas and Bcl-2 Expression on Peripheral Cells from Patients with Active Juvenile-Onset Systemic Lupus Erythematosus. J Rheum. 2007;34:1580–4.
    1. Seki M, Ushiyama C, Seta N, Abe K, Fukazawa T, Asakawa J, et al. Apoptosis of lymphocytes induced by glucocorticoids and relationship to therapeutic efficacy in patients with systemic lupus erythematosus. Arthritis Rheum. 1998;41:823–30.
    1. Korb LC, Ahearm JM. C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes. Complement deficiency and systemic lupus erythematosus revisited. J Immunol. 1997;158:4525–28.
    1. Pickering MC, Botto M, Taylor PR, Walport MJ. Systemic Lupus Erythematosus, complement deficiency, and apoptosis. Adv Immunol. 2000;76:227–34.
    1. Carneiro-Sampaio M, Liphaus BL, Jesus AA, Silva CAA, Oliveira JB, Kiss MH. Understanding Systemic Lupus Erythematosus Physiopathology in the Light of Primary Immunodeficiencies. J Clin Immunol. 2008;28:4–10.
    1. Navratil JS, Korb LC, Ahearn JM. Systemic lupus erythematosus and complement deficiency: clues to a novel role for the classical complement pathway in the maintenance of immune tolerance. Immunopharmacology. 1999;42:47–52.
    1. Manderson AP, Botto M, Walport MJ. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol. 2004;22:431–56.
    1. Potlukova E, Kralikova Et P. Complement Component C1q and anti-C1q Antibodies in Theory and in Clinical Pratice. Scand J Immunol. 2008;67:423–30.
    1. Sjöholm AG, Jönsson G, Braconier JH, Sturfelt G, Truedsson L. Complement deficiency and disease: an update. Mol Immunol. 2006;43:78–85.
    1. Sullivan KE. Genetics of Systemic Lupus Erythematosus. Clinical implications. Rheum Dis Clin of North Am. 2000;26:229–56.
    1. Prodeus AP, Goerg S, Shen LM, Pozdnyakova OO, Chu L, Alicot EM, et al. A critical role for complement in maintenance of self-tolerance. Immunity. 1998;9:721–31.
    1. Castellano G, Woltman AM, Nauta JA, Roos A, Trouw LA, Seelen MA, et al. Maturation of dendritic dcells abrogates C1q production in vivo and in vitro. Blood. 2004;103:3813–20.
    1. Botto M, Dell’Agnola C, Bygrave AE, Thompson EM, Cook HT, Petry F, et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet. 1998;19:56–9.
    1. Davies KA, Erlendsson K, Beynon HL, Peters AM, Steinsson K, Valdimarsson H, et al. Splenic uptake of immune complexes in man is complement-dependent. J Immunol. 1993;151:3866–73.
    1. Kim SJ, Gershov D, Ma X, Brot N, Elkon NB. I-PLA(2) activation during apoptosis promotes the expossure of membrane lysophosphatidylcholine leading to binding by natural immunoglobulin M antibodies and complement activation. J Exp Med. 2002;196:655–65.
    1. Jesus AA, Silva CA, Carneiro-Sampaio M, Scheinberg M, Mangueira CL, Marie SK, et al. Anti-C1q Antibodies in Juvenile-Onset Systemic Lupus Erythematosus. Ann N Y Acad Sci. 2009;1173:235–8.
    1. Bigler C, Schaller M, Perahud I, Osthoff M, Trendelenburg M. Autoantibodies against Complement C1q Specifically Target C1q Bound on Early Apoptotic Cells. J Immunol. 2009;183:3512–21.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren